Abstract
Aberrant gene expression is characteristic to all cancer cells and pathophysiology in general. Selective inhibition of constitutively elevated expression of oncogenes provides an opportunity to hinder the proliferation of malignant cells. Small synthetic molecules that specifically interfere with transcription and/or translation have great potential as anticancer drugs. Currently first-generation antisense oligonucleotides are widely used to inhibit the oncogene expression. The second generation of antisense agents have been studied mainly in vitro. One of these agents, peptide nucleic acid (PNA) is an oligonucleotide mimic with a noncharged achiral polyamide backbone to which the nucleobases are linked. PNA oligomers bind tightly to complementary DNA or RNA and are very stable in biological fluids. PNA can inhibit transcription and translation of target genes by specifically hybridizing to DNA or mRNA. The in vitro experiments showing inhibition of target protein expression by PNA have been followed by the first successful applications of PNA as an antisense agent in cultured cells and also in vivo. Hopefully this will lead to a wider use of PNA in the studies of cancer biology and therapy.
Current Cancer Drug Targets
Title: Targeting of Cancer-Related Proteins with PNA Oligomers
Volume: 1 Issue: 3
Author(s): Margus Pooga and Ulo Langel
Affiliation:
Abstract: Aberrant gene expression is characteristic to all cancer cells and pathophysiology in general. Selective inhibition of constitutively elevated expression of oncogenes provides an opportunity to hinder the proliferation of malignant cells. Small synthetic molecules that specifically interfere with transcription and/or translation have great potential as anticancer drugs. Currently first-generation antisense oligonucleotides are widely used to inhibit the oncogene expression. The second generation of antisense agents have been studied mainly in vitro. One of these agents, peptide nucleic acid (PNA) is an oligonucleotide mimic with a noncharged achiral polyamide backbone to which the nucleobases are linked. PNA oligomers bind tightly to complementary DNA or RNA and are very stable in biological fluids. PNA can inhibit transcription and translation of target genes by specifically hybridizing to DNA or mRNA. The in vitro experiments showing inhibition of target protein expression by PNA have been followed by the first successful applications of PNA as an antisense agent in cultured cells and also in vivo. Hopefully this will lead to a wider use of PNA in the studies of cancer biology and therapy.
Export Options
About this article
Cite this article as:
Margus Pooga and Ulo Langel , Targeting of Cancer-Related Proteins with PNA Oligomers, Current Cancer Drug Targets 2001; 1 (3) . https://dx.doi.org/10.2174/1568009013334142
DOI https://dx.doi.org/10.2174/1568009013334142 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hepatocyte Growth Factor Signaling in Cancer Metastasis
Current Signal Transduction Therapy Treatment of Estrogen Receptor-Positive Breast Cancer
Current Medicinal Chemistry Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Structural and Mechanistic Bases of the Anticancer Activity of Natural Aporphinoid Alkaloids
Current Topics in Medicinal Chemistry DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Recent Advances in the Use of Metallic Nanoparticles with Antitumoral Action - Review
Current Medicinal Chemistry Extrapituitary Actions of GnRH Antagonists: Prospects for in vitro Fertilization Programs
Current Pharmaceutical Design Machine Learning Methods in Precision Medicine Targeting Epigenetic Diseases
Current Pharmaceutical Design miR-221/222 Confers Radioresistance in Glioblastoma Cells Through Activating Akt Independent of PTEN Status
Current Molecular Medicine Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases
Mini-Reviews in Medicinal Chemistry Menthol – Pharmacology of an Important Naturally Medicinal “Cool”
Mini-Reviews in Medicinal Chemistry Synthesis of bis(indolyl)methanes Using Naturally Occurring, Biodegradable Itaconic Acid as a Green and Reusable Catalyst
Current Organic Synthesis Estrogen Regulation of MicroRNA Expression
Current Genomics Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development
Current Molecular Medicine Inhibitory Role of Resveratrol in the Development of Profibrogenesis and Fibrosis Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules
Current Drug Targets